AMLX — Q2 2026 Financial Report Analysis

Overview

Amylyx Pharmaceuticals had no product sales in the second quarter of 2026 — it pulled its ALS drug RELYVRIO off the market in April 2024 — so this quarter is about spending and cash, not revenue. The net loss was $43.4 million, slightly wider than a year earlier ($41.4 million), as legal costs and launch preparation pushed up overhead while research spending fell after the company dropped a trial in progressive supranuclear palsy (PSP). Cash and investments fell to $250.8 million. The more important news came after the quarter closed: on August 18 its lead drug, avexitide, passed its final-stage (Phase 3) LUCIDITY trial, and the next day the company sold about $472 million of new stock. That changes the funding picture this 10-Q describes.

At a glance

• Net loss of $43.4 million, up 4.8% — overhead (selling, general and administrative costs) rose 40% while research spending fell 13%, so the company spent more in total without a bigger research program to show for it.
• $29.0 million of cash used in the quarter (cash and investments went from $279.8 million at March 31 to $250.8 million at June 30) — about $10 million a month.
• About $472 million of new money raised on August 19 (14.09 million shares at $35.50), after the Phase 3 result — roughly 1.9 times the June 30 cash balance, at the cost of about 13% more shares.

Q2 2026 results

For the first half of 2026, the net loss was $84.7 million (vs $77.4 million), or $0.76 per share (vs $0.88). R&D was $51.4 million (vs $49.3 million) and SG&A $38.1 million (vs $31.3 million).

Where the research money went

The 10-Q breaks out direct R&D spending by program:

The whole R&D decline is the PSP program ending: the company says the decrease was "primarily due to a $7.1 million decrease in expenses related to AMX0035 for the treatment of PSP after its discontinuation," partly offset by $2.3 million more on avexitide and the LUCIDITY trial. Spending is now concentrated on one drug.

Why overhead jumped

SG&A rose $6.3 million. The filing attributes $5.6 million of that to consulting and professional services — "primarily due to increased spend for legal expenses related to the settlement of the February 2024 Shih Complaint" (a shareholder class action over statements about RELYVRIO's sales), plus marketing and commercial work ahead of a possible avexitide launch — and $1.0 million to hiring for pre-launch work. The company has agreed to settle the class action for $6.5 million, "a significant portion of which was funded by insurance," with a final court approval hearing set for September 10, 2026. Related derivative suits (claims brought on the company's behalf against current and former directors and officers) were still in settlement talks as of the filing.

What the headline numbers hide

• The smaller per-share loss comes from dilution, not improvement. The loss per share fell 15% (from $0.46 to $0.39) while the total loss grew 4.8%. The difference is the share count: 111.2 million average shares vs 89.1 million a year ago, after stock issued in 2025 (shares outstanding went from 89.2 million at June 30, 2025 to 109.9 million at December 31, 2025). The August 2026 offering adds another 14.09 million shares from the third quarter on.
• Cash burn is a bit lower than the loss, for routine reasons. For the first half, operating activities used $68.3 million against an $84.7 million net loss. The gap is mostly $14.4 million of stock-based compensation (employees paid in shares, a real cost to shareholders but not cash) and a $4.0 million milestone payment to research partner Gubra, which was expensed but shows up as investing cash. Working capital moved by only $0.4 million — there is no hidden build-up of unpaid bills.
• The quarter's overhead includes some one-off legal cost. Part of the SG&A jump is lawsuit settlement work that should fade once the settlements are approved. The rest — commercial and marketing build-out — is the opposite: it is the start of launch spending and should keep rising if avexitide moves toward approval.
• Interest income is propping up the bottom line a little. Other income of $2.3 million (vs $1.4 million) is mainly interest on cash and investments; with roughly $700 million now on hand after the raise, this line should grow, but it does not reflect the business itself.
• Commitments are building ahead of approval. At June 30 the company had $35.0 million of unconditional purchase obligations with manufacturers through 2028 ($13.6 million in the next 12 months). In September it added more: a supply agreement with Bachem and a term sheet with Polypeptide that includes a $30 million upfront capacity-reservation fee and minimum yearly purchases of avexitide drug substance from 2028 — spending committed before the FDA has reviewed the drug.

Takeaway: The Q2 financials describe a company spending about $10 million a month with $250.8 million left and no sales. Seven weeks later that picture is out of date: a clean Phase 3 win for avexitide and a ~$472 million stock sale mean the question is no longer whether Amylyx can fund itself to an FDA decision, but whether avexitide can win approval and sell into a small, newly defined market — with roughly 13% more shares in issue to share the outcome.

The events that changed the picture after June 30

• Phase 3 result (August 18). LUCIDITY, a 78-person, placebo-controlled trial in post-bariatric hypoglycemia (PBH — dangerous blood-sugar crashes some people develop after gastric bypass surgery), met its FDA-agreed main goal: a 55% reduction in the combined rate of moderate (Level 2) and severe (Level 3) hypoglycemic events versus placebo over 16 weeks (p=0.000003, meaning the result is extremely unlikely to be chance). It also met all secondary goals. The company reported no serious adverse events related to avexitide; the most common side effects were diarrhea and injection-site reactions. There is no FDA-approved treatment for PBH today; the company estimates about 160,000 people in the U.S. have it.
• Stock offering (August 19). 14.09 million shares at $35.50, for estimated net proceeds of about $471.7 million (about $542.5 million if underwriters bought the full 2.11 million-share option). The stated uses: a U.S. launch of avexitide if approved, securing manufacturing capacity, and R&D.
• Manufacturing deals (September). The Bachem agreement and Polypeptide term sheet described above, both non-exclusive, for commercial supply starting 2028.

Adding the offering's net proceeds to the June 30 balance gives roughly $722 million before third-quarter spending and the $30 million Polypeptide fee. The "runway into 2028" in the 10-Q was stated before the raise, so expect an updated (longer) figure with the Q3 report.

Outlook

Management's stated plan: submit a New Drug Application (the formal request for FDA approval) for avexitide in PBH by the end of 2026, with a commercial launch in 2027 if approved. Avexitide already has the FDA's Breakthrough Therapy Designation, which can speed the review. Behind it, AMX0318 — a longer-acting drug with the same mechanism, from the Gubra collaboration — is in pre-clinical safety studies with an Investigational New Drug filing (permission to start human trials) targeted for 2027; AMX0114 for ALS is in early dose-testing (Cohort 3 of four planned dose levels enrolling); and the company is still working with the FDA on a Phase 3 design for AMX0035 in Wolfram syndrome.

Our read: the financial risk has largely moved from "running out of money" to "execution." Costs should step up from here — SG&A as launch staffing and marketing build, plus manufacturing prepayments like the $30 million Polypeptide fee — so quarterly losses are likely to widen rather than narrow until there are sales. What to watch in the Q3 report (expected early November): whether the NDA timeline still says end of 2026, the updated cash runway, how quickly SG&A climbs, and whether the derivative-suit settlement is finalized. Longer term, the key unknown is commercial: PBH is a condition many doctors do not yet screen for, which is why the company started a disease-awareness campaign in June — sales will depend on how many of those estimated patients get diagnosed.